This paper introduces a novel pathway that
may be involved Inflammation-Associated sickness behaviors. The periphery-to-brain
communication pathway is described as bowel inflammation causing TNF-alpha
signaling, followed by microglia activation and monocyte infiltration into the
brain vasculature add parenchyma, which then results in the development of
sickness behaviors. Past studies have shown that probiotics aimed to teat
bowel-irritation has also improve sickness behaviors related to it. D’Mello et
al. then investigated if probiotics ingestion can alter this pathway and
reduced sickness behaviors.
D’Mello et al. studies their
hypothesis but using mice with liver inflammation due to bile duct ligation
(BDL). They established that BDL mice have increased sickness behaviors than
sham controlled mice through decreased social exploration found in BDL mice.
Next they administered VSL#3 treatment (a probiotic) to BDL mice and tested to
see changes in sickness behaviors and gut microbiome compared to controls. This
did not change the microbiome compared to sham mice and it significantly
improve sickness behaviors in BDL mice. To further test the pathway that may be
involved in this sickness behaviors, the authors studied how VSL#3 alters systemic
immunity and inflammatory monocyte recruitment to the brain in BDL mice. This treatment
showed an increase in cytokines in BDL mice, increased G-CSF, and decrease
TNF-alpha signaling in BDL mice. Sickness behaviors however were not different
between treated VSL#3 BDL mice and vehicle treated BDL mice. The authors
further tested microglia activation changes in treated VSL#3 BDL mice and
vehicle treated BDL mice. VSL#3 treated BDL mice showed more resting microglia
and decreased number of activated microglia and activated microglia expressing
TNF-alpha. The same results were shown in BDL mice treated with etanercept
which inhibits TNF-alpha. Lastly, monocyte infiltration was studied. VSL#3
treatment reduced number of monocyte infiltration and number of TNF-alpha-expressing
monocytes and the same results were found in BDL mice treated with etanercept.
These results show that VSL#3 treatment
does alter periphery-to-brain communication pathway and improves
sickness behaviors but does not necessarily link these to findings together. This
may mean that VSL#3 treatment may take part in improving sickness behaviors by
altering a different pathway and periphery-to-brain communication
pathway may be involved in a different symptom caused by irritable bowel
syndrome. Additionally, it is unclear how VSL#3 leads to changes in systemic
immunity since the gut microbiome was not changed in treated mice. More studies
need to be done to find other pathways involved in sickness behaviors such as vagal
afferent signaling and how probiotics change systemic immunity. Lastly, the
subjects in this study were all male mice. These future studies should aim to include
female mice since they may have differences in sickness behaviors and gut
microbiome.
I overall liked this paper because it
attempted to the mechanisms behind sickness behaviors and attempted to find a
treatment that could improve sickness behaviors. The paper provided more insight
on a pathway that may cause sickness behaviors and found improvements with a
probiotic. This may pave way for more studies to find potential probiotic treatments
for neuropsychiatric disorders.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.